KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Free Cash Flow (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Free Cash Flow for 16 consecutive years, with $217.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 29.45% to $217.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $644.6 million through Dec 2025, up 37.62% year-over-year, with the annual reading at $644.6 million for FY2025, 37.62% up from the prior year.
  • Free Cash Flow for Q4 2025 was $217.6 million at Halozyme Therapeutics, up from $173.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was $217.6 million in Q4 2025, with the low at $36.4 million in Q2 2021.
  • Average Free Cash Flow over 5 years is $101.7 million, with a median of $93.2 million recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 1880.59% in 2021, then tumbled 42.2% in 2022.
  • Over 5 years, Free Cash Flow stood at $82.5 million in 2021, then dropped by 7.27% to $76.5 million in 2022, then skyrocketed by 34.38% to $102.9 million in 2023, then surged by 63.41% to $168.1 million in 2024, then grew by 29.45% to $217.6 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $217.6 million, $173.3 million, and $99.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.